Europe Hematology & Flow Cytometry Markets Trends Explored in New VPG Study Published at MarketPublishers.сom18 Sep 2012 • by Natalie Aster
LONDON – The global hematology and flow cytometry markets are expected to undergo significant changes over the next five years due to the ongoing developments in molecular diagnostics, monoclonal antibodies, IT and laser technology in tandem with the deeper understanding of immunological factors that regulate systemic diseases.
Monoclonal antibody and molecular diagnostic tests are expected to make way for simple and sensitive assays. Smaller and conveniently operable laser systems are likely to expand the scope of flow cytometry applications to traditional clinical laboratories. Furthermore, chromosomal abnormalities, DNA content, and lymphocyte subsets analyses are also projected to become less tedious.
New market research report “Future Horizons in the European Hematology and Flow Cytometry Markets--France, Germany, Italy, Spain, UK: Supplier Shares and Sales Forecasts for 40 Tests by Country” drawn up by Venture Planning Group (VPG) sheds light on emerging opportunities in the hematology and flow cytometry markets in the five major European countries, including France, Germany, Italy, Spain and the UK, during the next five-year period.
The study explores future marketing and technological trends in the seven countries; provides market share estimates, test volume forecasts, and instrument placements; compares features of leading analyzers; profiles the top competitors and emerging market entrants; as well as suggests specific product and marketing opportunities for instrument and reagent suppliers.
Future Horizons in the European Hematology and Flow Cytometry Markets--France, Germany, Italy, Spain, UK: Supplier Shares and Sales Forecasts for 40 Tests by Country
Published: September, 2012
Price: US$ 18.500,00
More new market research reports by the publisher can be found at VPG page.